Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera
Abstract
:1. Introduction
2. Methods
2.1. Search Strategy
2.1.1. Ideal HCT and Difficulties in Focusing Solely on HCT in the Management of Low-Risk PV
2.1.2. Negative Outcomes Despite Achieving Target HCT in Low-Risk PV
2.1.3. Impaired QoL in Patients with Low-Risk PV
2.1.4. Phlebotomy, Iron Deficiency, and QoL in Low-Risk PV
2.1.5. Impact of Sexual, Social, and Psychological Issues on QoL
3. Quality-of-Life Assessment
4. Hydroxyurea
5. Peginterferon
6. Ruxolitinib
7. Erythrocytapheresis: Indications and Practical Considerations
8. Investigational Agents
9. Discussion
10. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Berglund, S.; Zettervall, O. Incidence of polycythemia vera in a defined population. Eur. J. Haematol. 1992, 48, 20–26. [Google Scholar] [CrossRef] [PubMed]
- Polycythemia, V. The natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann. Intern. Med. 1995, 123, 656–664. [Google Scholar]
- Tefferi, A.; Rumi, E.; Finazzi, G.; Gisslinger, H.; Vannucchi, A.; Rodeghiero, F.; Randi, M.L.; Vaidya, R.; Cazzola, M.; Rambaldi, A. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 2013, 27, 1874–1881. [Google Scholar] [CrossRef] [PubMed]
- Marchioli, R.; Finazzi, G.; Specchia, G.; Cacciola, R.; Cavazzina, R.; Cilloni, D.; De Stefano, V.; Elli, E.; Iurlo, A.; Latagliata, R. Cardiovascular events and intensity of treatment in polycythemia vera. New Engl. J. Med. 2013, 368, 22–33. [Google Scholar] [CrossRef]
- Gerds, A.T.; Mesa, R.A.; Burke, J.M.; Grunwald, M.R.; Stein, B.L.; Squier, P.; Yu, J.; Hamer-Maansson, J.; Oh, S.T. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: Analysis from REVEAL. Blood J. 2023, 143, 1646–1655. [Google Scholar] [CrossRef] [PubMed]
- Barbui, T.; Tefferi, A.; Vannucchi, A.M.; Passamonti, F.; Silver, R.T.; Hoffman, R.; Verstovsek, S.; Mesa, R.; Kiladjian, J.-J.; Hehlmann, R. Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia 2018, 32, 1057–1069. [Google Scholar] [CrossRef]
- Barbui, T.; Passamonti, F.; Accorsi, P.; Pane, F.; Vannucchi, A.M.; Velati, C.; Gale, R.P.; Tura, S.; Barosi, G. Evidence-and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia 2018, 32, 2077–2081. [Google Scholar] [CrossRef]
- Triguero, A.; Pedraza, A.; Pérez-Encinas, M.; Mata-Vázquez, M.I.; Vélez, P.; Fox, L.; Gómez-Calafat, M.; García-Delgado, R.; Gasior, M.; Ferrer-Marín, F. Low-risk polycythemia vera treated with phlebotomies: Clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Ann. Hematol. 2022, 101, 2231–2239. [Google Scholar] [CrossRef] [PubMed]
- Emanuel, R.; Marchioli, R.; Dueck, A.; Geyer, H.; Finazzi, G.; Cavazzina, R.; Masciulli, A.; Scarano, M.; Vannucchi, A.; Barbui, T. Impact of hematocrit on symptom burden among polycythemia vera patients. In Proceedings of the Haematologica; Ferrata Storti Foundation Via Giuseppe Belli: Pavia, Italy, 2013; pp. 118–119. [Google Scholar]
- Gordeuk, V.R.; Key, N.S.; Prchal, J.T. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. Haematologica 2019, 104, 653–658. [Google Scholar] [CrossRef] [PubMed]
- Spivak, J.L. Polycythemia vera: Myths, mechanisms, and management. Blood J. Am. Soc. Hematol. 2002, 100, 4272–4290. [Google Scholar] [CrossRef]
- Landolfi, R.; Di Gennaro, L.; Barbui, T.; De Stefano, V.; Finazzi, G.; Marfisi, R.; Tognoni, G.; Marchioli, R.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109, 2446–2452. [Google Scholar] [CrossRef]
- Berk, P. Treatment of polycythemia vera: A summary of clinical trials conducted by the polycythemia vera study group. In Polycythemia Vera and Myeloproliferative Disorders; WB Saunders: Philadelphia, PA, USA, 1995; pp. 166–194. [Google Scholar]
- Berk, P.; Goldberg, J.; Donovan, P.; Fruchtman, S.; Berlin, N.; Wasserman, L. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin. Hematol. 1986, 23, 132–143. [Google Scholar] [PubMed]
- Najean, Y.; Dresch, C.; Rain, J.D. The very-long-term course of polycythaemia: A complement to the previously published data of the Polycythaemia Vera Study Group. Br. J. Haematol. 1994, 86, 233–235. [Google Scholar] [CrossRef]
- Barbui, T.; Vannucchi, A.M.; Finazzi, G.; Finazzi, M.C.; Masciulli, A.; Carobbio, A.; Ghirardi, A.; Tognoni, G. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am. J. Hematol. 2017, 92, 1131–1136. [Google Scholar] [CrossRef] [PubMed]
- Silver, R.T.; Abu-Zeinah, G. Polycythemia vera: Aspects of its current diagnosis and initial treatment. Expert. Rev. Hematol. 2023, 16, 253–266. [Google Scholar] [CrossRef]
- Verstovsek, S.; Han, A.; Hayes, K.C.; Woody, T.; Valone, F.; Gupta, S.K. Real-world treatments and thrombotic events in polycythemia vera patients: A retrospective analysis between 2018–2019 in US population. Blood 2020, 136, 1–2. [Google Scholar] [CrossRef]
- Alvarez-Larrán, A.; Pérez-Encinas, M.; Ferrer-Marín, F.; Hernández-Boluda, J.C.; Ramírez, M.J.; Martínez-López, J.; Magro, E.; Cruz, Y.; Mata, M.I.; Aragües, P. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica 2017, 102, 103–109. [Google Scholar] [CrossRef]
- Mukhopadhyay, C.K.; Mazumder, B.; Fox, P.L. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J. Biol. Chem. 2000, 275, 21048–21054. [Google Scholar] [CrossRef]
- Barbui, T.; Carobbio, A.; Ghirardi, A.; Masciulli, A.; Rambaldi, A.; Vannucchi, A.M. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: Evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. Haematologica 2017, 102, e219–e221. [Google Scholar] [CrossRef]
- Griesshammer, M.; Kiladjian, J.-J.; Besses, C. Thromboembolic events in polycythemia vera. Ann. Hematol. 2019, 98, 1071–1082. [Google Scholar] [CrossRef] [PubMed]
- Boccia, R.V.; Stein, B.; Mesa, R.A.; Naim, A.B.; Cordaro, J.A.; Peng, W.; Sun, H.; Parasuraman, S.V.; Moliterno, A. Burden of phlebotomy in patients with polycythemia vera in the United States: Baseline data from the REVEAL study. Blood 2015, 126, 5187. [Google Scholar] [CrossRef]
- Ronner, L.; Podoltsev, N.; Gotlib, J.; Heaney, M.L.; Kuykendall, A.T.; O’Connell, C.; Shammo, J.; Fleischman, A.G.; Scherber, R.M.; Mesa, R. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood J. Am. Soc. Hematol. 2020, 135, 1696–1703. [Google Scholar] [CrossRef] [PubMed]
- Manoharan, A.; Gemmell, R.; Cavanaugh, L.; Shadood, N. Thrombosis in myeloproliferative neoplasms: A single center experience of using whole blood platelet aggregation studies for risk assessment and thromboprophylaxis. Clin. Appl. Thromb./Hemost. 2022, 28, 10760296221117482. [Google Scholar] [CrossRef]
- Mesa, R.A.; Niblack, J.; Wadleigh, M.; Verstovsek, S.; Camoriano, J.; Barnes, S.; Tan, A.D.; Atherton, P.J.; Sloan, J.A.; Tefferi, A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) An international internet-based survey of 1179 MPD patients. Cancer 2007, 109, 68–76. [Google Scholar] [CrossRef]
- Pieri, L.; Bogani, C.; Guglielmelli, P.; Zingariello, M.; Rana, R.A.; Bartalucci, N.; Bosi, A.; Vannucchi, A.M. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 2009, 94, 1537–1545. [Google Scholar] [CrossRef]
- Radia, D.; Geyer, H.L. Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematol. 2014 Am. Soc. Hematol. Educ. Program Book 2015, 2015, 340–348. [Google Scholar] [CrossRef]
- Kurzrock, R. The role of cytokines in cancer-related fatigue. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2001, 92, 1684–1688. [Google Scholar] [CrossRef]
- Johansson, P.; Mesa, R.; Scherber, R.; Abelsson, J.; Samuelsson, J.; Birgegård, G.; Andréasson, B. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk. Lymphoma 2012, 53, 441–444. [Google Scholar] [CrossRef]
- Abelsson, J.; Andréasson, B.; Samuelsson, J.; Hultcrantz, M.; Ejerblad, E.; Johansson, B. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk. Lymphoma 2013, 54, 2226–2230. [Google Scholar] [CrossRef]
- Ginzburg, Y.Z.; Feola, M.; Zimran, E.; Varkonyi, J.; Ganz, T.; Hoffman, R. Dysregulated iron metabolism in polycythemia vera: Etiology and consequences. Leukemia 2018, 32, 2105–2116. [Google Scholar] [CrossRef]
- Barosi, G.; Mesa, R.; Finazzi, G.; Harrison, C.; Kiladjian, J.-J.; Lengfelder, E.; McMullin, M.F.; Passamonti, F.; Vannucchi, A.M.; Besses, C. Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project. Blood J. Am. Soc. Hematol. 2013, 121, 4778–4781. [Google Scholar] [CrossRef] [PubMed]
- Emanuel, R.M.; Senyak, Z.; McCallister, A.; Cotter, M.; VanHusen, B.; Harrison, C.N.; Mesa, R.A. The MPN fatigue project: Stage 1 results of the MPN forum internet-based survey among 879 MPN Patients. Blood 2013, 122, 1595. [Google Scholar] [CrossRef]
- Geyer, H.L.; Andreasson, B.; Kosiorek, H.E.; Dueck, A.C.; Scherber, R.M.; Martin, K.A.; Butler, K.A.; Harrison, C.N.; Radia, D.H.; Cervantes, F. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer 2016, 122, 1888–1896. [Google Scholar] [CrossRef] [PubMed]
- Khalil, S.; Holy, M.; Grado, S.; Fleming, R.; Kurita, R.; Nakamura, Y.; Goldfarb, A. A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2. Blood Adv. 2017, 1, 1181–1194. [Google Scholar] [CrossRef] [PubMed]
- Cook, J.D.; Skikne, B.S.; Baynes, R.D. Iron deficiency: The global perspective. Prog. Iron Res. 1994, 356, 219–228. [Google Scholar]
- Ackrell, B.; Maguire, J.; Dallman, P.; Kearney, E. Effect of iron deficiency on succinate-and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria. J. Biol. Chem. 1984, 259, 10053–10059. [Google Scholar] [CrossRef]
- Oexle, H.; Gnaiger, E.; Weiss, G. Iron-dependent changes in cellular energy metabolism: Influence on citric acid cycle and oxidative phosphorylation. Biochim. Biophys. Acta (BBA)-Bioenerg. 1999, 1413, 99–107. [Google Scholar] [CrossRef]
- Song, J.; Kim, S.J.; Thiagarajan, P.; Prchal, J.T. Iron deficiency in polycythemia Vera increases HIF activity and transcription of prothrombotic genes. Blood 2021, 138, 2549. [Google Scholar] [CrossRef]
- Geyer, H.L.; Dueck, A.C.; Emanuel, R.M.; Cannon, K.; Kiladjian, J.-J.; Slot, S.; Zweegman, S.; Boekhorst, P.; Commandeur, S.; Schouten, H.C.; et al. Sexuality challenges, intimacy, and MPN symptom burden: An analysis by the MPN quality of life international study group (MPN-QOL ISG). Blood 2013, 122, 4088. [Google Scholar] [CrossRef]
- Scherber, R.; Dueck, A.C.; Johansson, P.; Barbui, T.; Barosi, G.; Vannucchi, A.M.; Passamonti, F.; Andreasson, B.; Ferarri, M.L.; Rambaldi, A. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood J. Am. Soc. Hematol. 2011, 118, 401–408. [Google Scholar] [CrossRef]
- Geyer, H.L.; Scherber, R.M.; Dueck, A.C.; Kiladjian, J.-J.; Xiao, Z.; Slot, S.; Zweegman, S.; Sackmann, F.; Fuentes, A.K.; Hernández-Maraver, D. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients. Blood J. Am. Soc. Hematol. 2014, 123, 3803–3810. [Google Scholar] [CrossRef] [PubMed]
- Neunteufl, T.; Heher, S.; Stefenelli, T.; Pabinger, I.; Gisslinger, H. Endothelial dysfunction in patients with polycythaemia vera. Br. J. Haematol. 2001, 115, 354–359. [Google Scholar] [CrossRef]
- Geyer, H.; Emanuel, R.; Dueck, A.; Kiladjian, J.; Xiao, Z.; Slot, S.; Zweegman, S.; Sackman, F.; Kerguelen Fuentes, A.; Hernandez-Maraver, D. Gender differences and MPN symptom burden: An analysis by the MPN quality of life international study group (MPN-QOL ISG); EHA Library: Hague, The Netherlands, 2014; pp. 396–397. [Google Scholar]
- Cella, D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin. Hematol. 1997, 34, 13–19. [Google Scholar]
- Mendoza, T.R.; Wang, X.S.; Cleeland, C.S.; Morrissey, M.; Johnson, B.A.; Wendt, J.K.; Huber, S.L. The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 1999, 85, 1186–1196. [Google Scholar] [CrossRef]
- Merup, M.; Åberg, W.; Löfvenberg, E.; Svensson, E.; Engman, K.; Paul, C.; Gardulf, A. Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol. 2002, 41, 50–55. [Google Scholar] [CrossRef]
- Mesa, R.A.; Schwager, S.; Radia, D.; Cheville, A.; Hussein, K.; Niblack, J.; Pardanani, A.D.; Steensma, D.P.; Litzow, M.R.; Rivera, C.E. The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk. Res. 2009, 33, 1199–1203. [Google Scholar] [CrossRef]
- Vannucchi, A.M.; Kiladjian, J.J.; Griesshammer, M.; Masszi, T.; Durrant, S.; Passamonti, F.; Harrison, C.N.; Pane, F.; Zachee, P.; Mesa, R. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New Engl. J. Med. 2015, 372, 426–435. [Google Scholar] [CrossRef]
- Mesa, R.; Miller, C.B.; Thyne, M.; Mangan, J.; Goldberger, S.; Fazal, S.; Ma, X.; Wilson, W.; Paranagama, D.C.; Dubinski, D.G. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: The MPN Landmark survey. BMC Cancer 2016, 16, 167. [Google Scholar] [CrossRef]
- Barbui, T.; Vannucchi, A.M.; De Stefano, V.; Masciulli, A.; Carobbio, A.; Ferrari, A.; Ghirardi, A.; Rossi, E.; Ciceri, F.; Bonifacio, M. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): A multicentre, randomised phase 2 trial. Lancet Haematol. 2021, 8, e175–e184. [Google Scholar] [CrossRef]
- Podoltsev, N.A.; Zhu, M.; Zeidan, A.M.; Wang, R.; Wang, X.; Davidoff, A.J.; Huntington, S.F.; Giri, S.; Gore, S.D.; Ma, X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Adv. 2018, 2, 2681–2690. [Google Scholar] [CrossRef] [PubMed]
- Vaddi, K.; Verstovsek, S.; Kiladjian, J.-J. Ruxolitinib: A targeted treatment option for patients with polycythemia vera. Blood Lymphat. Cancer Targets Ther. 2016, 6, 7–19. [Google Scholar]
- Kiladjian, J.-J.; Chevret, S.; Dosquet, C.; Chomienne, C.; Rain, J.-D. Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. J. Clin. Oncol. 2011, 29, 3907–3913. [Google Scholar] [CrossRef] [PubMed]
- Mesa, R.A.; Jamieson, C.; Bhatia, R.; Deininger, M.W.; Fletcher, C.D.; Gerds, A.T.; Gojo, I.; Gotlib, J.; Gundabolu, K.; Hobbs, G. NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. J. Natl. Compr. Cancer Netw. 2017, 15, 1193–1207. [Google Scholar] [CrossRef]
- Manoharan, A. Management of myelofibrosis with intermittent hydroxyurea. Br. J. Haematol. 1991, 77, 252–254. [Google Scholar] [CrossRef]
- Barbui, T.; Finazzi, G.; Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood J. Am. Soc. Hematol. 2013, 122, 2176–2184. [Google Scholar] [CrossRef]
- Barbui, T.; De Stefano, V.; Ghirardi, A.; Masciulli, A.; Finazzi, G.; Vannucchi, A.M. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera. Blood Cancer J. 2018, 8, 124. [Google Scholar] [CrossRef]
- Mesa, R.A.; Miller, C.B.; Mascarenhas, J.O.; Thyne, M.; Goldberger, S.; Paranagama, D.C.; Parasuraman, S.V.; Fazal, S.; Naim, A.B.; Mangan, J. Hydroxyurea treatment history and quality of life in patients with polycythemia vera: Results from the MPN landmark survey in the United States. Blood 2015, 126, 4077. [Google Scholar] [CrossRef]
- Maugeri, N.; Giordano, G.; Petrilli, M.; Fraticelli, V.; De Gaetano, G.; Cerletti, C.; Storti, S.; Donati, M. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: A new effect for an old drug? J. Thromb. Haemost. 2006, 4, 2593–2598. [Google Scholar] [CrossRef]
- Godfrey, A.L.; Campbell, P.J.; MacLean, C.; Buck, G.; Cook, J.; Temple, J.; Wilkins, B.S.; Wheatley, K.; Nangalia, J.; Grinfeld, J. Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features. J. Clin. Oncol. 2018, 36, 3361–3369. [Google Scholar] [CrossRef] [PubMed]
- Harrison, C.N.; Campbell, P.J.; Buck, G.; Wheatley, K.; East, C.L.; Bareford, D.; Wilkins, B.S.; van der Walt, J.D.; Reilly, J.T.; Grigg, A.P. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New Engl. J. Med. 2005, 353, 33–45. [Google Scholar] [CrossRef]
- Wang, R.; Shallis, R.M.; Stempel, J.M.; Huntington, S.F.; Zeidan, A.M.; Gore, S.D.; Ma, X.; Podoltsev, N.A. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Adv. 2023, 7, 734–743. [Google Scholar] [CrossRef] [PubMed]
- Najean, Y.; Rain, J.-D. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood J. Am. Soc. Hematol. 1997, 90, 3370–3377. [Google Scholar] [CrossRef]
- Spivak, J.L.; Hasselbalch, H. Hydroxycarbamide: A user’s guide for chronic myeloproliferative disorders. Expert. Rev. Anticancer. Ther. 2011, 11, 403–414. [Google Scholar] [CrossRef]
- Liu, D.; Xu, Z.; Zhang, P.; Qin, T.; Sun, X.; Qu, S.; Pan, L.; Ma, J.; Cai, W.; Liu, J. Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: A retrospective study based on 286 patients from a single center. Haematologica 2022, 107, 991–995. [Google Scholar] [CrossRef] [PubMed]
- Abu-Zeinah, G.; Silver, R.T.; Abu-Zeinah, K.; Scandura, J.M. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia 2022, 36, 569–572. [Google Scholar] [CrossRef]
- Gisslinger, H.; Klade, C.; Georgiev, P.; Krochmalczyk, D.; Gercheva-Kyuchukova, L.; Egyed, M.; Rossiev, V.; Dulicek, P.; Illes, A.; Pylypenko, H. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020, 7, e196–e208. [Google Scholar] [CrossRef]
- Mesa, R.A.; Hoffman, R.; Kosiorek, H.E.; Prchal, J.T.; Harrison, C.N.; McMullin, M.F.; Yacoub, A.; Rambaldi, A.; Berenzon, D.; Vannucchi, A.M. Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: Interim analysis results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial. Blood 2016, 128, 4271. [Google Scholar]
- Gisslinger, H.; Klade, C.; Georgiev, P.; Krochmalczyk, D.; Gercheva-Kyuchukova, L.; Egyed, M.; Dulicek, P.; Illes, A.; Pylypenko, H.; Sivcheva, L. S196: Ropeginterferon alfa-2B achieves patient-specific treatment goals in polycythemia vera: Final results from the PROUD-PV/CONTINUATION-PV studies. HemaSphere 2022, 6, 97–98. [Google Scholar] [CrossRef]
- Masarova, L.; Yin, C.C.; Cortes, J.E.; Konopleva, M.; Borthakur, G.; Newberry, K.J.; Kantarjian, H.M.; Bueso-Ramos, C.E.; Verstovsek, S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp. Hematol. Oncol. 2017, 6, 30. [Google Scholar] [CrossRef]
- Abu-Zeinah, G.; Krichevsky, S.; Cruz, T.; Hoberman, G.; Jaber, D.; Savage, N.; Sosner, C.; Ritchie, E.K.; Scandura, J.M.; Silver, R.T. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia 2021, 35, 2592–2601. [Google Scholar] [CrossRef]
- Passamonti, F.; Rumi, E.; Caramella, M.; Elena, C.; Arcaini, L.; Boveri, E.; Del Curto, C.; Pietra, D.; Vanelli, L.; Bernasconi, P. A dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis. Blood J. Am. Soc. Hematol. 2008, 111, 3383–3387. [Google Scholar] [CrossRef]
- Kiladjian, J.-J.; Klade, C.; Georgiev, P.; Krochmalczyk, D.; Gercheva-Kyuchukova, L.; Egyed, M.; Dulicek, P.; Illes, A.; Pylypenko, H.; Sivcheva, L. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 2022, 36, 1408–1411. [Google Scholar] [CrossRef]
- Lussana, F.; Carobbio, A.; Salmoiraghi, S.; Guglielmelli, P.; Vannucchi, A.M.; Bottazzi, B.; Leone, R.; Mantovani, A.; Barbui, T.; Rambaldi, A. Driver mutations (JAK2 V617F, MPL W515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J. Hematol. Oncol. 2017, 10, 54. [Google Scholar] [CrossRef]
- Bhuria, V.; Baldauf, C.K.; Schraven, B.; Fischer, T. Thromboinflammation in myeloproliferative neoplasms (MPN)—A puzzle still to be solved. Int. J. Mol. Sci. 2022, 23, 3206. [Google Scholar] [CrossRef] [PubMed]
- Verstovsek, S.; Passamonti, F.; Rambaldi, A.; Barosi, G.; Rosen, P.J.; Rumi, E.; Gattoni, E.; Pieri, L.; Guglielmelli, P.; Elena, C. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014, 120, 513–520. [Google Scholar] [CrossRef] [PubMed]
- Passamonti, F.; Griesshammer, M.; Palandri, F.; Egyed, M.; Benevolo, G.; Devos, T.; Callum, J.; Vannucchi, A.M.; Sivgin, S.; Bensasson, C. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study. Lancet Oncol. 2017, 18, 88–99. [Google Scholar] [CrossRef] [PubMed]
- Koschmieder, S.; Isfort, S.; Wolf, D.; Heidel, F.H.; Schafhausen, P.; Griesshammer, M.; Wolleschak, D.; Platzbecker, U.; Döhner, K.; Jost, P.J. Ruxolitinib shows efficacy in patients with newly-diagnosed polycythemia vera: Futility analysis of the randomized Ruxo-BEAT clinical trial of the German Study Group for myeloproliferative neoplasms. Blood 2019, 134, 2944. [Google Scholar] [CrossRef]
- Verstovsek, S.; Vannucchi, A.M.; Griesshammer, M.; Masszi, T.; Durrant, S.; Passamonti, F.; Harrison, C.N.; Pane, F.; Zachee, P.; Kirito, K. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016, 101, 821–829. [Google Scholar] [CrossRef]
- Tefferi, A.; Barbui, T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am. J. Hematol. 2020, 95, 1599–1613. [Google Scholar] [CrossRef]
- Ginzburg, Y.; Kirubamoorthy, K.; Salleh, S.; Lee, S.-E.; Lee, J.H.; Selvaratnam, V.; Gupta, S.K.; Valone, F.; Khanna, S.; Modi, N.B. Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy. Blood 2021, 138, 390. [Google Scholar] [CrossRef]
- Mascarenhas, J.; Passamonti, F.; Burbury, K.; El-Galaly, T.C.; Gerds, A.; Gupta, V.; Higgins, B.; Wonde, K.; Jamois, C.; Kovic, B. The MDM2 antagonist idasanutlin in patients with polycythemia vera: Results from a single-arm phase 2 study. Blood Adv. 2022, 6, 1162–1174. [Google Scholar] [CrossRef] [PubMed]
- Mascarenhas, J.; Lu, M.; Kosiorek, H.; Virtgaym, E.; Xia, L.; Sandy, L.; Mesa, R.; Petersen, B.; Farnoud, N.; Najfeld, V. Oral idasanutlin in patients with polycythemia vera. Blood J. Am. Soc. Hematol. 2019, 134, 525–533. [Google Scholar] [CrossRef] [PubMed]
- Lu, M.; Wang, X.; Li, Y.; Tripodi, J.; Mosoyan, G.; Mascarenhas, J.; Kremyanskaya, M.; Najfeld, V.; Hoffman, R. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood J. Am. Soc. Hematol. 2012, 120, 3098–3105. [Google Scholar] [CrossRef]
- Verstovsek, S.; Mesa, R.A.; Salama, M.E.; Li, L.; Pitou, C.; Nunes, F.P.; Price, G.L.; Giles, J.L.; D’Souza, D.N.; Walgren, R.A. A phase 1 study of the Janus kinase 2 (JAK2) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leuk. Res. 2017, 61, 89–95. [Google Scholar] [CrossRef]
- Rambaldi, A.; Iurlo, A.; Vannucchi, A.M.; Martino, B.; Guarini, A.; Ruggeri, M.; von Bubnoff, N.; De Muro, M.; McMullin, M.F.; Luciani, S. Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Blood Cancer J. 2021, 11, 53. [Google Scholar] [CrossRef]
- Snyder, C.F.; Aaronson, N.K. Use of patient-reported outcomes in clinical practice. Lancet 2009, 374, 369–370. [Google Scholar] [CrossRef]
- Arciero, V.; Santos, S.D.; Koshy, L.; Rahmadian, A.; Saluja, R.; Everest, L.; Parmar, A.; Chan, K.K. Assessment of Food and Drug Administration–and European Medicines Agency–approved systemic oncology therapies and clinically meaningful improvements in quality of life: A systematic review. JAMA Netw. Open 2021, 4, e2033004. [Google Scholar] [CrossRef]
- Conroy, T.; Paillot, B.; François, E.; Bugat, R.; Jacob, J.-H.; Stein, U.; Nasca, S.; Metges, J.-P.; Rixe, O.; Michel, P. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J. Clin. Oncol. 2005, 23, 1228–1236. [Google Scholar] [CrossRef]
- Basch, E. New frontiers in patient-reported outcomes: Adverse event reporting, comparative effectiveness, and quality assessment. Annu. Rev. Med. 2014, 65, 307–317. [Google Scholar] [CrossRef]
- Meropol, N.J.; Egleston, B.L.; Buzaglo, J.S.; Benson III, A.B.; Cegala, D.J.; Diefenbach, M.A.; Fleisher, L.; Miller, S.M.; Sulmasy, D.P.; Weinfurt, K.P. Cancer patient preferences for quality and length of life. Cancer 2008, 113, 3459–3466. [Google Scholar] [CrossRef]
- Rector Jr, W.G.; FORTUIN, N.J.; CONLEY, C.L. Non-hematologic effects of chronic iron deficiency: A study of patients with polycythemia vera treated solely with venesections. Medicine 1982, 61, 382–389. [Google Scholar] [CrossRef] [PubMed]
- Fazal, S.; Miller, C.B.; Mascarenhas, J.O.; Thyne, M.; Goldberger, S.; Paranagama, D.C.; Parasuraman, S.V.; Naim, A.B.; Mangan, J.; Mesa, R.A. Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States. Blood 2015, 126, 5184. [Google Scholar] [CrossRef]
- Tremblay, D.; Srisuwananukorn, A.; Ronner, L.; Podoltsev, N.; Gotlib, J.; Heaney, M.L.; Kuykendall, A.T.; O’Connell, C.L.; Shammo, J.M.; Fleischman, A. European LeukemiaNet (ELN) response predicts disease progression but not thrombosis or death in polycythemia vera (PV): An analysis of a multicenter database. Blood 2021, 138, 240. [Google Scholar] [CrossRef]
Author | Study | No. | Treatment | Findings |
---|---|---|---|---|
Marchioli 2013 [4] | Prospective | 222 | Phlebotomy with HCT <0.45 vs. HCT 0.45–0.50 | HCT > 0.45 increases four times cardiovascular death (p 0.007) |
Podoltsev 2018 [53] | Retrospective | 820 | No phlebotomy vs. Phlebotomy +HU vs. HU | Phlebotomy + HU improves O/S (p < 0.01) |
Barbui 2021 [52] | Prospective | 127 | Phlebotomy vs. Phlebotomy + ropeginterferon alfa-2b | Phlebotomy + ropeginterferon alfa-2b–effective in maintaining HCT (p 0.007) |
Vaddi 2016 [54] | Prospective | 222 | Ruxolitinib vs. BAT | HCT control and ≥35% reduction in spleen size with Ruxolitinib over BAT (p < 0.001). |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Visweshwar, N.; Fletcher, B.; Jaglal, M.; Laber, D.A.; Patel, A.; Eatrides, J.; Rathnakumar, G.R.; Iyer, K.V.; Ayala, I.; Manoharan, A. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera. J. Clin. Med. 2024, 13, 4952. https://doi.org/10.3390/jcm13164952
Visweshwar N, Fletcher B, Jaglal M, Laber DA, Patel A, Eatrides J, Rathnakumar GR, Iyer KV, Ayala I, Manoharan A. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera. Journal of Clinical Medicine. 2024; 13(16):4952. https://doi.org/10.3390/jcm13164952
Chicago/Turabian StyleVisweshwar, Nathan, Bradley Fletcher, Michael Jaglal, Damian A. Laber, Ankita Patel, Jennifer Eatrides, Geetha Rajasekharan Rathnakumar, Keshav Visweswaran Iyer, Irmel Ayala, and Arumugam Manoharan. 2024. "Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera" Journal of Clinical Medicine 13, no. 16: 4952. https://doi.org/10.3390/jcm13164952